Select Page

FAQ

Frequently Asked Questions

What is the CAMONX test?

It is a new non-invasive test for prostate cancer. It measures changes in the composition of prostate-proximal fluids caused by the disease. The test will be offered to GPs, urologists and patients through Cambridge Oncometrix laboratory located in the UK. Based on the test results the clinician and patients can decide whether or not to perform a prostate biopsy.

How did we discover the tumormarkers?

Cambridge Oncometrix has discovered and quantified a panel of substances (biomarkers) present in the prostatic gland, which change when affected by a malignant transformation. A set of non-protein biomarkers has been identified by making a direct comparison of carefully characterized prostate tissue samples taken from:

• 35 healthy men

• 45 men with Benign Prostatic Hyperplasia

• 60 men with Prostate Cancer

What is prostate-proximate fluid?

This term refers to the secretions of the prostatic gland, which can be found in expressed prostatic secretion and ejaculate.

When will the CAMONX test be available?

We aim to launch our test by 2021

What is the current status of test development?

Cambridge Oncometrix is currently conducting a pilot clinical trial abroad. However, in 2018 we plan to launch a clinical trial in the UK for regulatory approvals of the test.

Can I participate in the current or future study?

Yes. You can register your interest to participate in the planned UK study on our web page. You can also participate in the current clinical investigation. To do so you will need to travel to our clinical trial centre in St. Petersburg. However, we would not be able to reimburse you your travel and accommodation costs in Russia.

Can CAMONX test replace biopsy?

Needle biopsy remains the ‘gold standard’ diagnostic test for prostate cancer and will not be replaced by the CAMONX test.

Can the CAMONX test predict aggressiveness and size of the prostate cancer?

It is unknown yet. There are some indications that there is a correlation between the CAMONX markers and the aggressiveness of the tumor. We believe that our test will help patients and doctors to be able to identify who will benefit from prostate cancer treatment.

Is the CAMONX test protected by a patent?

Cambridge Oncometrix has filed a patent application on 45 prostate cancer biomarkers. Further patents are foreseen to cover the specific designs of the prophylactic and diagnostic devices.

For more information contact us